

Attorney Docket No.: 10211.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Mail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 37 CFR 1.53(b).

INVENTOR(S)		
First Name	Middle Name	Family Name or Surname
1. Alan 2. Kimberly 3. Elizabeth	1. 2. M. 3. J.	1. Klotz 2. Brown 3. Zaretsky
TITLE OF THE INVENTION		
Microbial Trypsin Mutants Having Chymotrypsin Activity And Nucleic Acids Encoding Same		

The following application parts are enclosed:

specification 66 pages Sequence Listing 8 pages
 Abstract 1 page Formal Drawings 10 pages

The filing fee is calculated as follows:

Basic Fee:	\$750.00
Total Claims: $21 - 20 = 1 \times 18 =$	\$18.00
Independent Claims: $3 - 3 = 0 \times 84 =$	\$0.00
Total Fee:	\$768.00

The benefit of U.S. provisional application no. 60/413,057 filed on September 24, 2002 is claimed under 35 U.S.C. 119(e).

An application data sheet is enclosed.

This application contains a Sequence Listing. Applicants submit a computer readable form of a sequence listing. The content of the paper copy and computer readable form is the same.

The assignee of the present application is:

Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
US

22388 U.S. PTO
10/669757
09/24/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application for
Title: Microbial Trypsin Mutants Having Chymotrypsin Activity And Nucleic Acids
Encoding Same
Applicants: Klotz et al.

Sir:

Express Mail Label No. ER 267577073 US

Date of Deposit: **September 24, 2003**

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 CFR §1.53(c) (in duplicate)
2. Application
3. Preliminary Amendment
4. Applicant Data Sheet
5. Unexecuted Combined Declaration and Power of Attorney
6. Sequence Listing & Diskette
7. Statement under 37 CFR 1.808
8. 10 sheets of drawings

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Seleste A. Buriani

(Name of person mailing paper(s) or fee)

Seleste A. Buriani

(Signature of person mailing paper(s) or fee)

Mailing Address:


Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

Applicants request that the assignee information be included in the published patent application.

Direct all correspondence to Customer Number: 25907.

Please charge the required fee, estimated to be \$750, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

Date: September 24, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Klotz et al.

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: September 24, 2003

Examiner: To be assigned

For: Microbial Trypsin Mutants Having Chymotrypsin Activity And Nucleic Acids Encoding Same

STATEMENT UNDER 37 C.F.R. 1.808

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The above-captioned application refers to deposit(s) of biological material which have been made at the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL) under the Budapest Treaty and assigned accession numbers **B-30627**.

All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the U.S. patent.

The deposit(s) will be maintained for (a) thirty years, (b) at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, or (c) the enforceable life of the U.S. patent granted from this application, whichever is longest. If the deposited material becomes inviable during the above term, the deposited material will be replaced.

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

Date: September 24, 2003